Mesoblast Limited MESO
13.65 USD -0.34 (-2.43%)
At closeNov 11, 2026, 6:27 PM EST
13.66 +0.01 +0.07%
After hours · Nov 11, 6:27 PM ET
13.64 Day range 14.20
11.95 52-week range 20.96
- YTD
- -24.33%
- 1 year
- -12.11%
News
globenewswire.com Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion…
globenewswire.com Mesoblast Board Changes NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Glaukos surged 17.4% premarket after strong Q3 results and raised FY26 sales guidance; INLF, NCPL and PCLA also rallied.
globenewswire.com Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for…
seekingalpha.com Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain Mesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Ryoncil's ongoing growth should also help finance MESO's remaining…
defenseworld.net Mesoblast (NASDAQ:MESO) Stock Price Breaks Below 50 Day Moving Average – Should You Sell? Mesoblast Limited (NASDAQ: MESO - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $15.78 and traded as low as…
benzinga.com Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities.…
globenewswire.com Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received…
defenseworld.net Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast Biogen (NASDAQ: BIIB - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the…
defenseworld.net Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average – Time to Sell? Mesoblast Limited (NASDAQ: MESO - Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $15.87 and traded as high…- benzinga.com Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39 Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
benzinga.com Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per…
seekingalpha.com Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
globenewswire.com Mesoblast Reports Substantial Revenue Growth to US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) --…
marketbeat.com Mesoblast H2 Earnings Call Highlights Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell…
benzinga.com Full Transcript: Mesoblast FY 2026 Earnings Call Mesoblast (NASDAQ:MESO) released full-year financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive…
benzinga.com Flowers Foods Posts Downbeat Q2 Results, Joins OSI Systems, Aveanna Healthcare And Other Big Stocks Moving Lower In Friday’s Pre-Market Session US stock futures rise, Dow up 150 points. Flowers Foods (NYSE:FLO) plunges on poor earnings & lowered forecast. Other stocks also down in pre-market.
zacks.com MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.
benzinga.com Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment Mesoblast Limited (NASDAQ:MESO) stock is trading higher on Monday after the company concluded patient dosing for its crucial Phase 3 clinical trial evaluating rexlemestrocel-L.
benzinga.com Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.
benzinga.com H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
globenewswire.com Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed…
benzinga.com Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.
globenewswire.com Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back…
zacks.com Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid…
globenewswire.com Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved…
seekingalpha.com Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Ryoncil's regulatory, reimbursement, and manufacturing precedents de-risk MESO's…
globenewswire.com Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil®…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
globenewswire.com Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures down, Nasdaq 100 futures drop over 1%. ON Semi to acquire Synaptics, ON shares fall 13%. Other stocks also down in pre-market.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Alpha Buying: Insider Conviction in High-Risk Biotech 
benzinga.com Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.
benzinga.com Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
benzinga.com Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.20) by 84.5 percent. This is a 99.26 percent increase over losses of $(4.20)…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com What's Next: Mesoblast's Earnings Preview 
benzinga.com Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy Mesoblast shares fall after new Ryoncil data show high survival in severe GVHD. Company plans adult trial as analysts keep Hold rating and stock trades near key levels.
benzinga.com Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication Mesoblast reports early real-world data showing 84% survival in children treated with FDA-approved Ryoncil, as the company expands hospital access and prepares an adult trial.
benzinga.com FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-stage trial.
benzinga.com Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session